Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Highly established clinical and imaging centers supporting first-in-human and multicenter studies.
Our state-of-the-art New Haven and London clinical trial imaging clinics are dedicated to harnessing advanced imaging biomarkers to support the development of novel therapies.
Together, they offer a combined 6000m² of clinical, laboratory, and office space equipped with advanced imaging capabilities, including PET, PET/CT, PET/MR, 3T MRI, and SPECT imaging.
Both sites feature GMP radiotracer manufacturing, specialized radiochemistry support, multi-modal capabilities, and robust recruitment and regulatory expertise.
Early-phase and late-phase multi-center clinical imaging site
Serve as an expert clinical site, recruiting, and managing patients through course of study with onsite clinicians and imaging capabilities.
Proven track record in translational imaging, with expert support for submissions, including medical writing, consulting, and IND development, review, and filing.
Co-localized with radiochemistry, overcoming logistical hurdles of tracer distribution.
Disease-agnostic imaging expertise across body regions, with specialized capabilities in target occupancy, dosimetry services, and tracer evaluation, powered by a robust imaging platform.
Specialized expertise in Neuroscience diseases including Parkinson’s and Alzheimer’s clinical trials.
Focused scientific, operational, and quality assurance teams ensuring compliant, phase-appropriate study execution for biopharma sponsors.
Determine the suitability of the radiotracer to provide quantitative information on the biological target or process of interest.
Identify physiological changes due to disease, age, or genetic status.
Measure drug concentration in tissue over time.
Determine the relationship between plasma concentration and biological target occupancy.
Assess changes in pharmacodynamic responses as a function of therapeutic candidate dose.
Initial evaluation of a novel radiotracer to assess its suitability as a tool compound for the biological target or process of interest.
Characterization of the whole body and/or organ-specific distribution of a radiotracer over time to assess the energy deposition in tissue and correlate this to a defined measure of harm (Rem or Sievert).
A study to determine the change in biological process or target of interest over time.
A research study conducted across multiple locations, often involving treatment with a drug and/or placebo, with imaging included for the full study or as a sub-study.
Perceptive supports imaging-based studies for eligibility, safety, or biomarker assessments, serving as an imaging center for subjects at single specialty centers or multi-site national and international trials.
Our expertise includes site coordination, patient travel logistics, scan acquisition, arterial/venous line placement, and metabolite analysis.
A study examining biological markers—such as proteins, genes, or molecules—to improve understanding of health and disease, aiding in diagnosis, treatment planning, prediction, and tracking treatment success.
Perceptive’s image analysis team brings extensive expertise in PET imaging, leveraging state-of-the-art modeling, method development, and advanced imaging platforms to support exploratory image analysis in early clinical trials.
Our specialists apply machine learning and artificial intelligence to deliver precise quantification, with proven experience translating methods across species from preclinical to clinical studies. This comprehensive approach ensures reliable insights for PET and SPECT projects, driving success from early-phase research through late-stage trials.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
